

ITRASKIN[®] Oral Solution

ANTIFUNGAL.



Itraskin[®], oral suspension, is recommended for the treatment of fungal infections caused by microorganisms susceptible to Itraconazole, such as skin dermatophytosis caused by *Microsporum canis* in cats, dermatitis caused by *Malassezia pachydermatis* in dogs and systemic infections of fungal origin, such as, histoplasmosis, cryptococcosis, blastomycosis and sporotrichosis.

Technical Specification

SPECIES

Dogs and cats.

DOSAGE FORM

Oral suspension.

THERAPEUTIC ACTION

Antifungal.

COMPOSITION

Each mL of suspension contains:
Itraconazole.....20 mg
Excipients q.s.p.....1 mL

PROPERTIES

Itraconazole is a synthetic antifungal agent, belonging to the family of azole derivatives. It was introduced in the 90s in order to broaden the antifungal spectrum, increase its potency compared to other azoles and reduce adverse effects at the digestive level, especially in prolonged therapies. The antifungal action of Itraconazole is generated through a multiple mechanism initiated by the inhibition of two cytochromes P450 involved in the biosynthesis of Ergosterol: CYP51 (sterol-14 alpha demethylase) and CYP61 (Delta 22-denaturase). Ergosterol is an essential component of the plasma membrane of fungi.

INDICATIONS

Itraskin[®], oral suspension, is recommended for the treatment of fungal infections caused by microorganisms susceptible to Itraconazole, such as skin dermatophytosis caused by *Microsporum canis* in cats, dermatitis caused by *Malassezia pachydermatis* in dogs and systemic infections of

fungal origin, such as, histoplasmosis, cryptococcosis, blastomycosis and sporotrichosis.

ROUTE OF ADMINISTRATION AND DOSAGE

Orally.

Recommended dose:

Cats:

Pathology

Dose

1 mL every 2 Kg of weight
(equivalent to 10 mg/kg)
every 24 hours, for 4 weeks.

Dermatophytosis by *Microsporum canis*:

It is recommended to
continue the therapy until
mycological cure or lack of
dermatophyte isolation in
three consecutive weekly
cultures.

Systemic fungal infections (histoplasmosis, cryptococcosis, blastomycosis, etc.):

0.5 mL every 2 of weight
(equivalent to 5 mg/kg)
every 12 hours, or 1 ml
every 2 Kg of weight
(equivalent to 10 mg/kg)
every 24 hours. The
therapy should be
continued for 2 to 3 months
or until 1 month after the
resolution of the clinical
signs of the animal.

Dogs:

Patología Dermatitis por *Malassezia* *pachydermatis*:

Dosis

2,5 mL cada 10 kg de peso (equivalentes a 5
mg/kg)
cada 24 horas, por 3 semanas.

Enfermedades fúngicas sistémicas (blastomycosis, histoplasmosis, sporotrichosis, etc.):

2,5 mL cada 10 kg de peso (equivalentes a 5
mg/kg)
cada 24 horas, por 2 a 3 meses, o hasta después de
1
mes de la resolución de los signos clínicos del
animal.

DRUG INTERACTIONS

- Itraconazole absorption is reduced by administration in conjunction with proton pump inhibitor antacids (Omeprazole) and H2 blockers (Cimetidine, Ranitidine, etc.) or Didanosine.
- Itraconazole can increase prothrombin times in patients receiving Warfarin or other coumarin anticoagulants. Rifampin can increase the metabolism of Itraconazole.
- Itraconazole can increase the serum levels of oral antidiabetic agents (eg Chlorpropamide, Glipizide etc.), which can lead to hypoglycemia.
- Do not use in conjunction with Cisapride, as it can cause ventricular arrhythmias.
- Itraconazole interacts with certain antihistamines (Terfenadine, Astemizole), Benzodiazepines, calcium channel blockers, anticonvulsants, some antimicrobials and Cyclosporine.
- It is not recommended to use concomitantly with anticholinergics.

CONTRAINDICATIONS

-
- Do not use in patients with hypersensitivity to itraconazole or other azole agents.
 - Do not use in patients with hepatic impairment or hypochlorhydria.
 - Do not use in females during the gestation and lactation period.
 - Do not use in dogs and cats under 2 months of age.

PRECAUTIONS

- It is recommended to administer the drug in conjunction with food, to increase its bioavailability.
- It is recommended to monitor the appetite of treated individuals.
- In prolonged treatments or in patients with particular risk conditions, it is recommended to monitor liver enzymes routinely (monthly ALT).

SPECIAL PRECAUTIONS FOR THE OPERATOR

- Wash your hands after administering the product.
- In the case of contact with the eyes, it is recommended to wash with plenty of water for 15 minutes.
- In case of accidental ingestion do not induce vomiting. Obtain medical attention if necessary.

WARNINGS

Keep out of the reach of children

ADVERSE EFFECTS

In dogs, the most common adverse effect is anorexia, especially with higher doses. Some cases may show signs of hepatotoxicity, in which case treatment should be discontinued at least temporarily. Liver damage is determined by increased ALT activity. Anorexia is often a symptomatic marker of toxicity and usually occurs in the second month of treatment. Some dogs treated with doses of 10 mg / kg may develop vasculitis or ulcerative skin lesions and edema of the limbs that may require a reduction of the dose to 5 mg / kg. These problems usually resolve after stopping the medication. In cats, adverse effects are dose related. Gastrointestinal effects (anorexia, weight loss, vomiting), hepatotoxicity (increased ALT, jaundice), and depression have been reported. If adverse effects occur and ALT is elevated, the drug should be discontinued. Enzyme hyperactivity in the absence of other signs does not necessarily require reducing the dose or stopping the medication. Once ALT levels normalize and other adverse effects decrease, and if necessary, the drug can be restarted at half the dose initially used with closer clinical supervision.

CONSERVATION

- Store at room temperature between 15 ° and 30 ° C.
- Once opened, use the product within 3 months. Discard the unused product after that period of time.

CONDITION OF SALE

Sale with veterinary prescription.

PRESENTATION

Battle with 120 mL

PREPARED BY

Laboratorio Drag Pharma Chile Invetec S.A.

RECORDS

Chile: Reg. SAG N° 2053

Costa Rica: Reg. N° MAG CL4-15-13-5639

Rep. Dominicana: Reg. N° 9305

Bolivia: Reg. SENASAG PUV-F N°007252/16

COUNTRIES WHERE IT IS MARKETED

Imported and distributed in Bolivia by:

ZOOFARMA

TEL: +(591)222-3357

Street Díaz Romero 1339, La Paz.

Imported and Distributed in Peru by:

Representaciones Durand SAC.

Av. Manuel Olguin N ° 501 Office N ° 604

Santiago de Surco Lima.

You have entered drug info or veterinary products intended exclusively (s) kind (s) indicated (s).

Drag Pharma Lab is not responsible for the consequences of misuse of the products, and the use of this information without consulting a veterinarian